Read more
The discovery of the anti-tumour activity of cisplatin in 1965 and its subsequent introduction into clinical trials in 1971 was the catalyst for a major research effort into the potential of metal compounds in cancer therapy. This book draws together information on all metals involved in cancer therapy, including those used in radioisotopes. Throughout an interdisciplinary approach has been taken to reflect the nature of this research. This book will provide an invaluable reference source for anyone interested in the role of metals in oncotherapy.
List of contents
List of contributors. Preface. Introduction. Platinum anticancer drugs. Gold. Ruthenium compounds in cancer therapy. Rhodium, iridium and palladium compounds as experimental anticancer drugs. Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes - early transition metal antitumour drugs. Antitumour activity of tin compounds. Gallium compounds in cancer therapy. Bleomycin and metal interactions. The in vivo use of metallic radioisotopes in cancer detection and imaging. Index.
Summary
The discovery of the anti-tumour activity of cisplatin in 1965, and its subsequent introduction into clinical trials in 1971, was the catalyst for a major research effort into the potential of metal compounds in cancer therapy. This book provides a discussion of metal compounds in cancer therapy.
